While I’m on chemo, can I still have a glass of wine or a beer with dinner?

 

Ask a Question

Q: While I’m on chemotherapy, can I still have a glass of wine or a beer with dinner? 

A: Drinking alcohol—whether wine, beer, or liquor—may interfere with some chemotherapy drugs and can cause dehydration. Find out from your doctor or others on your health care team if having one drink with dinner is okay with the chemotherapy medication you’re taking. We tell our patients not to have alcohol the day before, day of, and day after chemotherapy.

Alcohol also can worsen some chemotherapy side effects, such as mouth sores. If the mouth becomes sore, alcohol can cause burning and additional dryness of the mouth. Some patients report that taste changes from chemotherapy or radiation to the head and neck make alcohol less enjoyable.

If it doesn’t conflict with your treatment medication, having a drink with dinner might help you relax and improve your appetite. But limit yourself to one drink. Excessive drinking is dangerous. Be sure your doctor knows the amount of alcohol you were drinking before treatment began, so you can get help with cutting back now if needed.
--Kathy Newman, RN, BSN

If you’re experiencing an upset stomach or nausea from chemotherapy, try a soothing cup of homemade ginger tea between or during meals.

Latest Cancer News
Avastin® Linked with Increased Risk of Blood Clots

November 20, 2008 — According to a combined analysis of previously published studies, cancer patients who use Avastin® (bevacizumab) may have an increased risk of venous thromboembolism (a blood clot in a vein). These results were published in the Journal of the American Medical Association.

Addition of Avastin® to Paraplatin®, Taxol®, and Erbitux® Promising for Advanced NSCLC

November 20, 2008 — Researchers affiliated with the Southwest Oncology Group have reported that the four-drug combination of chemotherapy agents Paraplatin® (carboplatin) and Taxol® (paclitaxel) plus targeted therapies Avastin® (bevacizumab) and Erbitux® (cetuximab) is safe and may improve survival in patients with advanced non–small cell lung cancer (NSCLC). The details of this study were presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology November 13-15.

Avastin® Increases Risk of Venous Thromboembolism

November 20, 2008 — Researchers from Stony Brook University have reported that the use of Avastin® (bevacizumab) increases the risk of thromboembolism. The details of this review were published in the November 19, 2008 issue of the Journal of the American Medical Association.

Select news items provided by Reuters Health